Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-19
2008-12-30
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S259100, C514S262100, C514S265100, C514S300000, C514S303000, C544S253000, C544S255000, C544S262000, C546S113000, C546S114000, C546S115000, C546S118000
Reexamination Certificate
active
07470693
ABSTRACT:
The invention is directed to compounds having the following Formula I:and methods of using them for the treatment of proliferative diseases.
REFERENCES:
patent: 6214344 (2001-04-01), Schwall et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6858626 (2005-02-01), Xue et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 2005/0239820 (2005-10-01), Borzilleri et al.
patent: 2005/0245530 (2005-11-01), Borzilleri et al.
patent: 2005/0288289 (2005-12-01), Crispino et al.
patent: 2005/0288290 (2005-12-01), Borzilleri et al.
patent: 2006/0004006 (2006-01-01), Borzilleri et al.
patent: 2006/0009453 (2006-01-01), Geuns-Meyer et al.
patent: 0 138 757 (1984-08-01), None
patent: WO 2004/085399 (2004-10-01), None
patent: WO 2005/005389 (2005-01-01), None
U.S. Appl. No. 11/292,358, filed Dec. 1, 2005, Borzilleri et al.
Sonnenberg, E. et al., “Scatter Factor/Hepatocyte Growth Factor and Its Receptor, the c-met Tyrosine Kinase, Can Mediate a Signal Exchange between Mesenchyme and Epithelia during Mouse Development”,The Journal of Cell Biology,vol. 123, No. 1, pp. 223-235 (Oct. 1993).
Matsumoto, K. et al., “Hepatocyte Growth Factor: Molecular Structure, Roles in Liver Regeneration, and Other Biological Functions”,Critical Reviews in Oncogenesis,3(1,2), pp. 27-54 (1992).
Stoker, M. et al., “Scatter factor is a fibroblast-derived modulator of epithelial cell mobility”,Nature,vol. 327, pp. 239-242 (May 1987).
Montesano, R. et al., “Identification of a Fibroblast-Derived Epithelial Morphogen as Hepatocyte Growth Factor”,Cell,vol. 67, pp. 901-908 (Nov. 29, 1991).
Stella, M.C. et al., “Molecules in focus—HGF: a multifunctional growth factor controlling cell scattering”,The International Journal of Biochemistry&Cell Biology,vol. 31, pp. 1357-1362 (1999).
Stuart, K.A. et al. “Hepatocyte growth factor/scatter factor-induced intracellular signalling”,Int. J. of Exp. Path.,vol. 81, pp. 17-30 (2000).
Bussolino, F. et al., “Hepatocyte Growth Factor Is a Potent Angiogenic Factor Which Stimulates Endothelial Cell Motility and Growth”, TheJournal of Cell Biology,vol. 119, No. 3, pp. 629-641 (Nov. 1992).
Park, M. et al., “Sequence ofMETprotooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors”,Proc. Natl. Acad. Sci. USA,vol. 84, pp. 6379-6383 (Sep. 1987).
Bottaro, D.P. et al., “Identification of the Hepatocyte Growth Factor Receptor as thec-metProto-Oncogene Product”,Science,vol. 251, pp. 802-804 (Feb. 15, 1991).
Furge, K.A. et al., “Met receptor tyrosine kinase: enhanced signaling through adapter proteins”,Oncogene,vol. 19, pp. 5582-5589 (2000).
Gual, P. et al., “Sustained recruitment of phospholipase C-γ to Gab 1 is required for HGF-induced branching tubulogenesis”,Oncogene,vol. 19, pp. 1509-1518 (2000).
Schaeper, U. et al., “Coupling of Gab1 to c-Met, Grb2, and Shp2 Mediates Biological Responses”,The Journal of Cell Biology,vol. 149, No. 7, pp. 1419-1432 (Jun. 26, 2000).
Bardelli, A. et al., “Comcomitant activation of pathways downstream of Grb2 and Pl 3-kinase is required forMET-mediated metastasis”,Oncogene,vol. 18, pp. 1139-1146 (1999).
Sachs, M. et al., “Essential Role of Gab1 for Signaling by the c-Met Receptor In Vivo”,The Journal of Cell Biology,vol. 150, No. 6, pp. 1375-1384 (Sep. 18, 2000).
Tanimura, S. et al., “Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering”,Oncogene,vol. 17, pp. 57-65 (1998).
Lai, J-F et al., “Involvement of Focal Adhesion Kinase in Hepatocyte Growth Factor-induced Scatter of Madin-Darby Canine Kidney Cells*”,The Journal of Biological Chemistry,vol. 275, No. 11, pp. 7474-7480 (2000).
Lubensky, I.A. et al., “Hereditary and Sporadic Papillary Renal Carcinomas withc-metMutations Share a Distinct Morphological Phenotype”,American Journal of Pathology,vol. 155, No. 2, pp. 517-526 (Aug. 1999).
Christiansen, J.G. et al., “A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo”,Cancer Research,vol. 63, pp. 7345-7355 (Nov. 1, 2003).
Lee, J-H et al., “A novel germ line juxtamembraneMetmutation in human gastric cancer”,Oncogene,vol. 19, pp. 4947-4953 (2000).
Di Renzo, M.F. et al., “Overexpression and Amplification of the Met/HGF Receptor Gene during the Progression of Colorectal Cancer”,Clinical Cancer Research,vol. 1, pp. 147-154 (Feb. 1995).
Rong, S. et al., “Met Proto-oncogene Product Is Overexpressed in Tumors of p53-deficient Mice and Tumors of Li-Fraumeni Patients”,Cancer Research,vol. 55, pp. 1963-1970 (May 1, 1995).
Rong, S. et al., “Met Expression and Sarcoma Tumorigenicity”,Cancer Research,vol. 53, pp. 5355-5360 (Nov. 15, 1993).
Kenworthy, P. et al., “The presence of scatter factor in patients with metastatic spread to the pleura”,Br. J. Cancer,vol. 66, pp. 243-247 (1992).
Scarpino, S. et al., “Hepatocyte Growth Factor (HGF) Stimulates Tumour Invasiveness in Papillary Carcinoma of the Thyroid”,Journal of Pathology,vol. 189, pp. 570-575 (1999).
Soman, N.R. et al., “TheTPR-METoncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions”,Proc. Natl. Acad. Sci. USA,vol. 88, pp. 4892-4896 (Jun. 1991).
Camp, R.L. et al., “MetExpression Is Associated with Poor Outcome in Patients with Axillary Lymph Node Negative Breast Carcinoma”,Cancer,vol. 86, No. 11, pp. 2259-2265 (Dec. 1, 1999).
Masuya, D. et al., “The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients”,British Journal of Cancer,vol. 90, pp. 1555-1562 (2004).
Takayama, H. et al., “Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor”,Proc. Natl. Acad. Sci. USA,vol. 94, pp. 701-706 (Jan. 1997).
Cooper, C.S. et al., “Amplification and overexpression of themetgene in spontaneously transformed NIH3T3 mouse fibroblasts”,The EMBO Journal,vol. 5, No. 10, pp. 2623-2628 (1986).
Stabile, L.P. et al., “Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy”,Gene Therapy,vol. 11, pp. 325-335 (2004).
Jiang, W.G. et al., “Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET”, vol. 9, pp. 4274-4281 (Sep. 15, 2003).
CHEMCATS, Pharma Library Collection, Accession No. 2001:47043. CAS Registry No. 313648-77-0, Publication date: Mar. 15, 2005.
CHEMCATS, Pharma Library Collection, Accession No. 2001:20477 CAS Registry No. 313223-37-9, Publication date: Mar. 15, 2005.
Borzilleri Robert M.
Cornelius Lyndon A. M.
Schroeder Gretchen M.
Bristol--Myers Squibb Company
Davis Zinna N
Gibbons Maureen S.
Greenblatt Gary D.
LandOfFree
Oxalamide derivatives as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxalamide derivatives as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxalamide derivatives as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4026714